Business Wire

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

Share

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally.

“As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere.”

The Company’s CUSIP number will remain unchanged. In addition, the Company stock codes and stock names for The Stock Exchange of Hong Kong and the STAR Market of the Shanghai Stock Exchange will not change. No action by the Company’s shareholders is required to implement the Nasdaq ticker symbol change.

The Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, with a presentation at 1:30 pm PT. The live webcast of the event can be accessed from the Investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 30 days following the event.

About BeiGene

BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s leadership in oncology; BeiGene’s ability to advance its hematology franchise and solid tumor pipeline and the related impact on patients; and BeiGene’s plans, commitments, aspirations and goals under the caption “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

To access BeiGene media resources, please visit ourNews & Mediasite.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241223168194/en/

Contacts

Investor Contact
Liza Heapes
+1 857-302-5663
ir@beigene.com

Media Contact
Kyle Blankenship
+1 667-351-5176
media@beigene.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases23.12.2024 14:00:00 EET | Press release

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co., Ltd. (Representative Corporate Officer and CEO: Haruo Naito; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai") announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases. Fujirebio and Eisai have been conducting joint research on cerebrospinal fluid biomarkers related to Alzheimer’s disease (AD). The two companies have agreed to move forward with their partnership based on the shared understanding that the development and commercialization of diagnostic methods for neurodegenerative diseases can be accelerated by integrating the long-standing respective expertise of Fujirebio, which has experience in the

Hyatt Discloses Exclusive Discussions With Playa Hotels & Resorts N.V.23.12.2024 13:20:00 EET | Press release

Hyatt Hotels Corporation (the “Company” or “Hyatt”) (NYSE: H) today disclosed it has executed an exclusivity agreement with Playa Hotels & Resorts N.V. (“Playa”) (NASDAQ: PLYA) under which Playa has agreed to negotiate exclusively with Hyatt regarding potential strategic alternatives, which may include the acquisition of Playa by Hyatt. Mark S. Hoplamazian, President and Chief Executive Officer of Hyatt, said, "Playa has been a valuable partner for many years, is one of the world’s strongest operators of all-inclusive resorts, and owns a premier portfolio of high-quality, high-end all-inclusive resorts in iconic locations and key markets across the Caribbean and Mexico. Strategic alternatives under consideration could have compelling strategic merit to add new incremental durable fee streams for Hyatt. We remain steadfastly committed to our asset-light business model and if this process continues, we will continue to map out a clear path for an asset-light outcome for any strategic alt

ARIA Sensing Unveils "Hydrogen" — The World’s First 3D UWB Radar System-On-Chip23.12.2024 09:26:00 EET | Press release

ARIA Sensing proudly announces the launch of "Hydrogen," a groundbreaking Ultra-Wideband (UWB) Radar System-On-Chip (SoC) that sets a new industry benchmark as the first to offer 3D beamforming with programmable bandwidth up to 1.8 GHz. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218452155/en/ Hydrogen, the world's first UWB Radar SoC for 3D detection, of the Italian company ARIA Sensing (Photo: Business Wire) The "Hydrogen" SoC introduces advanced waveforms supporting both single-pulse and pulse-compression capabilities, delivering unparalleled precision in radar sensing applications. Equipped with two integrated RISC-V microprocessors, the chip ensures robust performance and flexibility for a variety of use cases. Key features of "Hydrogen" include: 4Tx and 4Rx UWB channels: Allowing flexible and scalable array configurations for optimized 3D imaging and radar detection. Advanced 3D Beamforming: Providing accurate de

Moutai's Global Brand Cultural Event Concludes in Italy22.12.2024 19:10:00 EET | Press release

The 2024 Global Brand Cultural Event hosted by Kweichow Moutai Group recently concluded successfully in Italy. Leveraging liquor as a cultural bridge between East and West, the event charted new pathways and milestones for Chinese brands, exemplified by Kweichow Moutai Group, in their global outreach. It also fostered deeper cultural exchange and mutual understanding between China and Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241222852417/en/ Gao Shan introduced Moutai to the guests at the event in Rome. (Photo: Business Wire) As part of the event, Moutai organized two grand themed tasting dinners in Milan and Rome. Gao Shan, Chairman of the Labor Union of Kweichow Moutai Distillery (Group) Co., Ltd., highlighted Italy's longstanding support in Moutai’s international journey, noting that the brand has been exported to Italy since the 1970s. Quoting Italian President Sergio Mattarella during his visit to China, Ga

Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 20:41:00 EET | Press release

On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye